gambisan

Herbal extract formula composed of four medicinal herbs (Ephedra intermedia Schrenk (12 g), Gypsum Fibrosum (16 g), Atractylodes lancea DC. (8 g), and Thea sinensis L. (20 g))

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Lee, Jae-Dong: 2 articles (11/2019 - 01/2013)
2.	Jo, Dae-Hyun: 1 article (11/2019)
3.	Lee, Seunghoon: 1 article (11/2019)
4.	Huh, Jeong-Eun: 1 article (01/2013)
5.	Kang, Jung Won: 1 article (01/2013)
6.	Kim, Kun Hyung: 1 article (01/2013)
7.	Nam, Dongwoo: 1 article (01/2013)

Related Diseases

1.	Obesity 01/01/2013 - "Gambisan could act as a possible therapeutic agent for obesity. " 11/01/2019 - "Effects of Gambisan in overweight adults and adults with obesity: A retrospective chart review." 11/01/2019 - "A retrospective chart review was conducted to explore the effect of Gambisan, a granular extract of novel herbal medicine, for short-term (≤16 weeks) weight loss in adults who are overweight and those with obesity. "
2.	Overweight 11/01/2019 - "Effects of Gambisan in overweight adults and adults with obesity: A retrospective chart review." 11/01/2019 - "A retrospective chart review was conducted to explore the effect of Gambisan, a granular extract of novel herbal medicine, for short-term (≤16 weeks) weight loss in adults who are overweight and those with obesity. "
3.	Weight Loss (Weight Reduction) 11/01/2019 - "Despite limitations in interpreting the results of this retrospective medical record review, Gambisan induced statistically and clinically meaningful weight loss with a tolerable level of AEs. " 11/01/2019 - "A retrospective chart review was conducted to explore the effect of Gambisan, a granular extract of novel herbal medicine, for short-term (≤16 weeks) weight loss in adults who are overweight and those with obesity. "
4.	Body Weight (Weight, Body) 11/01/2019 - "The effectiveness of Gambisan was primarily evaluated by comparing body weight (BW) at baseline and endpoint, using paired t tests; the safety of Gambisan was evaluated on the basis of adverse events (AEs) experienced by patients. "